HomeMarketsSharesBAILLIE GIFFORD US GROWTH TRUST

Trade BAILLIE GIFFORD US GROWTH TRUST - USA CFD

Market is not available at the momentMarket information is presented
as of 2026-10-05T15:27:23+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.023
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
£1,000.00
Overnight funding adjustment
Charges from full value of position
-0.021276 %
(-£4.26)

Trade size with leverage ~ £20,000.00

Money from leverage ~ $£19,000.00


-0.02128%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
£1,000.00
Overnight funding adjustment
Charges from full value of position
-0.000642 %
(-£0.13)

Trade size with leverage ~ £20,000.00

Money from leverage ~ $£19,000.00


-0.00064%
Overnight funding adjustment time21:00 (UTC)
CurrencyGBP
Min traded quantity10
Margin5.00%
Stock exchangeGreat Britain
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close3.831
Open3.776
1-Year Change38.98%
Day's Range3.776 - 3.871

Trade BAILLIE GIFFORD US GROWTH TRUST - USA

About Baillie Gifford US Growth Trust PLC

Baillie Gifford US Growth Trust plc is a United Kingdom-based investment company. The Company’s investment objective is to produce long term capital growth. The Company invests predominantly in equities of companies which are incorporated or domiciled, or which conduct a significant portion of their business, in the United States. The Company's portfolio consists of direct holdings in listed securities and unlisted securities in up to a combined maximum of 90 companies or funds, with 30 or more listed security holdings. The Company invests in various sectors, including consumer discretionary, consumer staples, financials, healthcare, industrials, information technology, materials, and real estate. Baillie Gifford & Co Limited is the alternative investment fund manager.

Financial summary

BRIEF: For the six months ended 30 November 2021, Baillie Gifford US Growth Trust PLC revenues decreased 40% to £159.5M. Net income decreased 41% to £155.8M. Revenues reflect Movement in investment holding gains decrease of 53% to £108.4M, Currency (losses)/gains decrease from £492K to -£1.5M, Income from investments and interest rec decrease of 14% to £281K. Net income also reflects Bank loan increase from £165K to £369K (expense).

Latest shares articles

BNP Paribas stock forecast
BNP Paribas stock forecast: Q2 earnings beat estimates
BNP Paribas is a French banking group whose recent developments include a Swift ledger transaction with HSBC for Siemens and continued focus on eurozone interest rates. Explore third-party BNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
13 hours ago
Boeing stock forecast
Boeing stock forecast: FAA investigates Miami freighter crash
Boeing is a US aerospace manufacturer whose shares remain in focus after a 767-300 freighter crash in Miami prompted an FAA investigation. Explore third-party BA price targets and technical analysis. Past performance is not a reliable indicator of future results.
14 hours ago
CaixaBank stock forecast
CaixaBank stock forecast: BPI exits Angola market
CaixaBank is a Spanish bank whose Portuguese unit, Banco BPI, agreed to sell its 33.35% stake in Banco de Fomento de Angola for €388.5m. Explore third-party CABK price targets and technical analysis. Past performance is not a reliable indicator of future results.
15 hours ago
Valneva stock forecast
Valneva stock forecast: EMA validates Lyme vaccine application
Valneva is a French vaccine company listed on Euronext Paris. In August, the EMA validated the marketing-authorisation application for its Lyme disease vaccine candidate with Pfizer. Explore third-party VLA price targets. Past performance is not a reliable indicator of future results.
18 hours ago

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready